Sponsor: CG Oncology, Inc.
Sponsor Study ID: PIVOT-006
Study Title: A Phase 3, Randomized Study of CG0070 versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor
CTO #: 103976
NCT Number:
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder
Study Objectives: To evaluate the recurrence free survival (RFS) of transurethral resection of bladder tumor (TURBT) followed by cretostimogene versus TURBT followed by observation in participants with intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC).